Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,592 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial.
Wang X, Kang X, Zhang R, Xue L, Xu J, Zhao X, Ou Q, Yu N, Feng G, Li J, Zheng Z, Chen X, Wang Z, Zheng Q, Li Y, Qin J, Bi N, Li Y. Wang X, et al. Among authors: yu n. Clin Cancer Res. 2024 Nov 15;30(22):5061-5072. doi: 10.1158/1078-0432.CCR-24-1236. Clin Cancer Res. 2024. PMID: 39544026 Clinical Trial.
Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study.
Yu N, Cheng G, Li J, Liang J, Zhang T, Deng L, Liu W, Wang J, Zhai Y, Wang W, Xiao Z, Zhou Z, Chen D, Feng Q, Bi N, Wang X. Yu N, et al. Curr Cancer Drug Targets. 2023;23(8):653-662. doi: 10.2174/1568009623666230315145937. Curr Cancer Drug Targets. 2023. PMID: 36924100 Clinical Trial.
Conversion chemoradiotherapy combined with nab-paclitaxel plus cisplatin in patients with locally advanced borderline-resectable or unresectable esophageal squamous cell carcinoma: a phase i/ii prospective cohort study.
Yu N, Chen X, Li J, Kang X, Wang Z, Zhang R, Qin J, Li Y, Zheng Q, Feng G, Deng L, Zhang T, Wang W, Liu W, Wang J, Feng Q, Lv J, Zhou Z, Xiao Z, Bi N, Li Y, Wang X. Yu N, et al. Strahlenther Onkol. 2024 Dec;200(12):1038-1046. doi: 10.1007/s00066-024-02286-8. Epub 2024 Aug 12. Strahlenther Onkol. 2024. PMID: 39134689 Free PMC article. Clinical Trial.
S-1-based concurrent chemoradiotherapy plus nimotuzumab in patients with locally advanced esophageal squamous cell carcinoma who failed neoadjuvant therapy: a real-world prospective study.
Wang X, Feng G, Yang X, Yu N, Zheng Z, Li J, Kang X, Chen X, Zhang R, Li Y, Wang Z, Deng L, Zhang T, Liu W, Wang J, Wang W, Feng Q, Xiao Z, Zhou Z, Bi N, Li Y, Qin J. Wang X, et al. Among authors: yu n. Cancer Biol Ther. 2024 Dec 31;25(1):2417464. doi: 10.1080/15384047.2024.2417464. Epub 2024 Oct 27. Cancer Biol Ther. 2024. PMID: 39462770 Free PMC article.
Effectiveness and safety of combined nimotuzumab and S-1 chemotherapy with concurrent radiotherapy for locally advanced esophageal cancer in malnourished and elderly patients: A prospective phase II study.
Feng G, Li J, Yu N, Zheng Z, Yang X, Deng L, Zhang T, Wang W, Liu W, Wang J, Feng Q, Lyu J, Xiao Z, Zhou Z, Bi N, Qin J, Wang X. Feng G, et al. Among authors: yu n. Chin J Cancer Res. 2024 Jun 30;36(3):270-281. doi: 10.21147/j.issn.1000-9604.2024.03.04. Chin J Cancer Res. 2024. PMID: 38988486 Free PMC article.
3,592 results